# Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

Source: https://onco.cc/trials/nct04159818/  
OnCo record `nct04159818` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nivolumab and cisplatin in triple-negative breast cancer, run by The Netherlands Cancer Institute, now recruiting.

## Summary

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients is a phase 2, randomised interventional study registered as NCT04159818 by The Netherlands Cancer Institute, with a registry enrolment figure of 52 participants, started 2020-02-21 and due to reach its primary completion in 2022-12-15. Interventions recorded: Nivolumab; Cisplatin; Low dose doxorubicin. Conditions listed: Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: "* Metastatic or incurable locally advanced triple negative breast cancer (ER \< 10%, HER2 IHC 0,1+ or 2+ with no amplification)". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TONIC-2
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04159818
- Phase: 2
- Setting: Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients: the TONIC-2 Trial
- Sponsor: The Netherlands Cancer Institute
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT04159818: https://clinicaltrials.gov/study/NCT04159818

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04159818.json